King pharmaceuticals inc, Actavis elizabeth llc, Ekr therapeutics inc, App pharmaceuticals llc, Baxter healthcare corp anesthesia and critical care, Hospira inc, Mallinckrodt chemical inc, Meridian medical technologies inc, Watson laboratories inc, Roxane laboratories inc, Clonmel healthcare ltd, Endo pharmaceuticals inc, Kv pharmaceutical co, Mallinckrodt inc, Purdue pharma lp, Xanodyne pharmaceutics inc, Actavis • Morphine is used for the management of chronic, moderate to severe pain. Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.
Morphine is an opioid agonist used for the relief of moderate to severe acute and chronic pain.
Morphine-6-glucuronide is responsible for approximately 85% of the response observed by morphine administration. Morphine and its metabolites act as agonists of the mu and kappa opioid receptors. The mu-opioid receptor is integral to morphine's effects on the ventral tegmental area of the brain. Morphine's activation of the reward pathway is mediated by agonism of the delta-opioid receptor in the nucleus accumbens, while modification of the respiratory system and addiction disorder are mediated by agonism of the mu-opioid receptor.
